Skip to main content
SpringerLink
Log in

The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells

  • Chapter
  • First Online:
Stem Cells Heterogeneity in Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1139))

Abstract

Osteosarcoma is the most common bone sarcoma and is one of the cancer entities characterized by the highest level of heterogeneity in humans. This heterogeneity takes place not only at the macroscopic and microscopic levels, with heterogeneous micro-environmental components, but also at the genomic, transcriptomic and epigenetic levels. Recent investigations have revealed the existence in osteosarcoma of cancer cells with stemness properties. Cancer stem cells are characterized by their specific phenotype and low cycling capacity, and are linked to drug resistance, tumour growth and the metastatic process. In addition, cancer stem cells contribute to the enrichment of tumour heterogeneity. The present manuscript will describe the main characteristic features of cancer stem cells in osteosarcoma and will discuss their impact on maintaining tumour heterogeneity. Their clinical implications will also be briefly addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR, Iwakuma T (2010) CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 70:4602–4612

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Alfranca A, Martinez-Cruzado L, Tornin J, Abarrategi A, Amaral T, de Alava E, Menendez P, Garcia-Castro J, Rodriguez R (2015) Bone microenvironment signals in osteosarcoma development. Cell Mol Life Sci 72:3097–3113

    Article  CAS  PubMed  Google Scholar 

  • Avnet S, Di Pompo G, Chano T, Errani C, Ibrahim-Hashim A, Gillies RJ, Donati DM, Baldini N (2017) Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation. Int J Cancer 140:1331–1345

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Baglio SR, Lagerweij T, Pérez-Lanzón M, Ho XD, Léveillé N, Melo SA, Cleton-Jansen AM, Jordanova ES, Roncuzzi L, Greco M, van Eijndhoven MAJ, Grisendi G, Dominici M, Bonafede R, Lougheed SM, de Gruijl TD, Zini N, Cervo S, Steffan A, Canzonieri V, Martson A, Maasalu K, Köks S, Wurdinger T, Baldini N, Pegtel DM (2017) Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression. Clin Cancer Res 23:3721–3733

    Article  CAS  PubMed  Google Scholar 

  • Basu-Roy U, Seo E, Ramanathapuram L, Rapp TB, Perry JA, Orkin SH, Mansukhani A, Basilico C (2012) Sox2 maintains self-renewal of tumor-initiating cells in osteosarcomas. Oncogene 31:2270–2282

    Article  CAS  PubMed  Google Scholar 

  • Basu-Roy U, Bayin NS, Rattanakorn K, Han E, Placantonakis DG, Mansukhani A, Basilico C (2015) Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun 6:6411

    Article  CAS  PubMed  Google Scholar 

  • Bousquet M, Noirot C, Accadbled F, Sales de Gauzy J, Castex MP, Brousset P, Gomez-Brouchet A (2016) Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann Oncol 27:738–744

    Article  CAS  PubMed  Google Scholar 

  • Brown HK, Tellez-Gabriel M, Heymann D (2017) Cancer stem cells in osteosarcoma. Cancer Lett 386:189–195

    Article  CAS  PubMed  Google Scholar 

  • Brown HK, Schiavone K, Gouin F, Heymann MF, Heymann D (2018a) Biology of bone sarcomas and new therapeutic developments. Calcif Tissue Int 102:174–195

    Article  CAS  PubMed  Google Scholar 

  • Brown HK, Tellez-Gabriel M, Cartron PF, Vallette FM, Heymann MF, Heymann D (2018b) Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: myth or reality? Drug Discov Today. https://doi.org/10.1016/j.drudis.2018.11.017

  • Chano T, Kita H, Avnet S, Lemma S, Baldini N (2018) Prominent role of RAB39A-RXRB axis in cancer development and stemness. Oncotarget 9:9852–9866

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH (2016) A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. Cold Spring Harb Mol Case Stud 2:a000992

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Chen F, Zeng Y, Qi X, Chen Y, Ge Z, Jiang Z, Zhang X, Dong Y, Chen H, Yu Z (2018) Targeted salinomycin delivery with EGFR and CD133 aptamers based dual-ligand lipid-polymer nanoparticles to both osteosarcoma cells and cancer stem cells. Nanomedicine 14:2115–2127

    Article  CAS  PubMed  Google Scholar 

  • Cortini M, Avnet S, Baldini N (2017) Mesenchymal stroma: role in osteosarcoma progression. Cancer Lett 405:90–99

    Article  CAS  PubMed  Google Scholar 

  • D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL (2018) Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov 8:944–957

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • de Groot AE, Roy S, Brown JS, Pienta KJ, Amend SR (2017) Revisiting seed and soil: examining the primary tumor and cancer cell foraging in metastasis. Mol Cancer Res 15:361–370

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Di Fiore R, Drago-Ferrante R, Pentimalli F, Di Marzo D, Forte IM, Carlisi D, De Blasio A, Tesoriere G, Giordano A, Vento R (2016) Let-7d miRNA shows both antioncogenic and oncogenic functions in osteosarcoma-derived 3AB-OS cancer stem cells. J Cell Physiol 231:1832–1841

    Article  PubMed  CAS  Google Scholar 

  • Dumars C, Ngyuen JM, Gaultier A, Lanel R, Corradini N, Gouin F, Heymann D, Heymann MF (2016) Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget 7:78343–78354

    Article  PubMed  PubMed Central  Google Scholar 

  • Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S (2017) Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics. Oncotarget 8:48794–48806

    Article  PubMed  Google Scholar 

  • Feng H, Tillman H, Wu G, Davidoff AM, Yang J (2018) Frequent epigenetic alterations in polycomb repressive complex 2 in osteosarcoma cell lines. Oncotarget 9:27087–27091

    Article  PubMed  PubMed Central  Google Scholar 

  • Franzetti GA, Laud-Duval K, van der Ent W, Brisac A, Irondelle M, Aubert S, Dirksen U, Bouvier C, de Pinieux G, Snaar-Jagalska E, Chavrier P, Delattre O (2017) Cell-to-cell heterogeneity of EWSR1-FLI1 activity determines proliferation/migration choices in Ewing sarcoma cells. Oncogene 36:3505–3514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y (2009) Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 34:1381–1386

    CAS  PubMed  Google Scholar 

  • Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T (2014) Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells 32:959–973

    Article  CAS  PubMed  Google Scholar 

  • Funes JM, Quintero M, Henderson S, Martinez D, Qureshi U, Westwood C, Clements MO, Bourboulia D, Pedley RB, Moncada S, Boshoff C (2007) Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A 104:6223–6228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gambera S, Abarrategi A, González-Camacho F, Morales-Molina Á, Roma J, Alfranca A, García-Castro J (2018) Clonal dynamics in osteosarcoma defined by RGB marking. Nat Commun 9:3994

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Georges S, Calleja LR, Jacques C, Lavaud M, Moukengue B, Lecanda F, Quillard T, Gabriel MT, Cartron PF, Baud’huin M, Lamoureux F, Heymann D, Ory B (2018) Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma. Oncotarget 9:35726–35741

    Article  PubMed  PubMed Central  Google Scholar 

  • Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, Ghivizzani SC, Ignatova TN, Steindler DA (2005) Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 7:967–976

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Glumac PM, LeBeau AM (2018) The role of CD133 in cancer: a concise review. Clin Transl Med 7:18

    Article  PubMed  PubMed Central  Google Scholar 

  • Gonçalves JM, Silva CAB, Rivero ERC, Cordeiro MMR (2019) Inhibition of cancer stem cells promoted by Pimozide. Clin Exp Pharmacol Physiol 46(2):116–125

    Article  PubMed  CAS  Google Scholar 

  • Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481:306–313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Greco N, Schott T, Mu X, Rothenberg A, Voigt C, McGough RL 3rd, Goodman M, Huard J, Weiss KR (2014) ALDH activity correlates with metastatic potential in primary sarcomas of bone. J Cancer Ther 5:331–338

    Article  PubMed  PubMed Central  Google Scholar 

  • Guo X, Yu L, Zhang Z, Dai G, Gao T, Guo W (2017) miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1. Cancer Cell Int 17:29

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Guth AM, Deogracias M, Dow SW (2014) Comparison of cancer stem cell antigen expression by tumor cell lines and by tumor biopsies from dogs with melanoma and osteosarcoma. Vet Immunol Immunopathol 161:132–140

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Halldorsson A, Brooks S, Montgomery S, Graham S (2009) Lung metastasis 21 years after initial diagnosis of osteosarcoma: a case report. J Med Case Rep 3:9298

    Article  PubMed  PubMed Central  Google Scholar 

  • He A, Qi W, Huang Y, Feng T, Chen J, Sun Y, Shen Z, Yao Y (2012) CD133 expression predicts lung metastasis and poor prognosis in osteosarcoma patients: a clinical and experimental study. Exp Ther Med 4:435–441

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • He A, Yang X, Huang Y, Feng T, Wang Y, Sun Y, Shen Z, Yao Y (2015) CD133(+) CD44(+) cells mediate in the lung metastasis of osteosarcoma. J Cell Biochem 116:1719–1729

    Article  CAS  PubMed  Google Scholar 

  • Heymann MF, Brown HK, Heymann D (2016) Drugs in early clinical development for the treatment of osteosarcoma. Expert Opin Investig Drugs 25:1265–1280

    Article  CAS  PubMed  Google Scholar 

  • Heymann MF, Lézot F, Heymann D (2017) The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma. Cell Immunol. https://doi.org/10.1016/j.cellimm.2017.10.011

  • Hochane M, Trichet V, Pecqueur C, Avril P, Oliver L, Denis J, Brion R, Amiaud J, Pineau A, Naveilhan P, Heymann D, Vallette FM, Olivier C (2017) Low-dose pesticide mixture induces senescence in normal mesenchymal stem cells (MSC) and promotes tumorigenic phenotype in premalignant MSC. Stem Cells 35:800–811

    Article  CAS  PubMed  Google Scholar 

  • Honoki K, Fujii H, Kubo A, Kido A, Mori T, Tanaka Y, Tsujiuchi T (2010) Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance. Oncol Rep 24:501–5015

    Article  CAS  PubMed  Google Scholar 

  • Itoh H, Kadomatsu T, Tanoue H, Yugami M, Miyata K, Endo M, Morinaga J, Kobayashi E, Miyamoto T, Kurahashi R, Terada K, Mizuta H, Oike Y (2018) TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma. Oncogene 37:2903–2920

    Article  CAS  PubMed  Google Scholar 

  • Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Dürr HR, Rechl H, Schaser KD, Melcher I, Burdach S, Kulozik A, Specht K, Heinimann K, Fulda S, Bielack S, Jundt G, Tomlinson I, Korbel JO, Nathrath M, Baumhoer D (2015) Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun 6:8940

    Article  CAS  PubMed  Google Scholar 

  • La Noce M, Paino F, Mele L, Papaccio G, Regad T, Lombardi A, Papaccio F, Desiderio V, Tirino V (2018) HDAC2 depletion promotes osteosarcoma’s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy. J Exp Clin Cancer Res 37:296

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Lamora A, Talbot J, Mullard M, Brounais-Le Royer B, Redini F, Verrecchia F (2016) TGF-β Signaling in bone remodeling and osteosarcoma progression. J Clin Med 5(11):E96

    Article  PubMed  CAS  Google Scholar 

  • Lamoureux F, Baud’huin M, Rodriguez Calleja L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE, Heymann D, Ory B (2014) Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat Commun 5:3511

    Article  PubMed  CAS  Google Scholar 

  • Li J, Zhong XY, Li ZY, Cai JF, Zou L, Li JM, Yang T, Liu W (2013) CD133 expression in osteosarcoma and derivation of CD133+ cells. Mol Med Rep 7:577–584

    Article  CAS  PubMed  Google Scholar 

  • Li Y, Xian M, Yang B, Ying M, He Q (2017) Inhibition of KLF4 by statins reverses Adriamycin-induced metastasis and cancer stemness in osteosarcoma cells. Stem Cell Rep 8:1617–1629

    Article  CAS  Google Scholar 

  • Li B, Wang Z, Wu H, Xue M, Lin P, Wang S, Lin N, Huang X, Pan W, Liu M, Yan X, Qu H, Sun L, Li H, Wu Y, Teng W, Wang Z, Zhou X, Chen H, Poznansky MC, Ye Z (2018) Epigenetic regulation of CXCL12 plays a critical role in mediating tumor progression and the immune response in osteosarcoma. Cancer Res 78:3938–3953

    Article  CAS  PubMed  Google Scholar 

  • Liu F, Li L, Li Y, Ma X, Bian X, Liu X, Wang G, Zhang D (2018) Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV. Int J Oncol 53:2010–2020

    CAS  PubMed  PubMed Central  Google Scholar 

  • López-Lázaro M (2018) The stem cell division theory of cancer. Crit Rev Oncol Hematol 123:95–113

    Article  PubMed  Google Scholar 

  • Lu J, Song G, Tang Q, Yin J, Zou C, Zhao Z, Xie X, Xu H, Huang G, Wang J, Lee DF, Khokha R, Yang H, Shen J (2017) MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1. Oncogene 36:231–241

    Article  CAS  PubMed  Google Scholar 

  • Makena MR, Ranjan A, Thirumala V, Reddy A (2018) Cancer stem cells: road to therapeutic resistance and strategies to overcome resistance. Biochim Biophys Acta Mol basis Dis. https://doi.org/10.1016/j.bbadis.2018.11.015

  • Martins-Neves SR, Lopes AO, do Carmo A, Paiva AA, Simoes PC, Abrunhosa AJ, Gomes CM (2012) Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line. BMC Cancer 12:139

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Martins-Neves SR, Corver WE, Paiva-Oliveira DI, van den Akker BE, Briaire-de-Bruijn IH, Bovee JV, Gomes CM, Cleton-Jansen AM (2016a) Osteosarcoma stem cells have active Wnt/beta-catenin and overexpress SOX2 and KLF4. J Cell Physiol 231:876–886

    Article  CAS  PubMed  Google Scholar 

  • Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovee JV, Cleton-Jansen AM, Gomes CM (2016b) Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/beta-catenin signaling. Cancer Lett 370:286–295

    Article  CAS  PubMed  Google Scholar 

  • Martins-Neves SR, Paiva-Oliveira DI, Fontes-Ribeiro C, Bovée JVMG, Cleton-Jansen AM, Gomes CMF (2018) IWR-1, a tankyrase inhibitor, attenuates Wnt/β-catenin signaling in cancer stem-like cells and inhibits in vivo the growth of a subcutaneous human osteosarcoma xenograft. Cancer Lett 414:1–15

    Article  CAS  PubMed  Google Scholar 

  • Mesiano G, Grignani G, Fiorino E, Leuci V, Rotolo R, D’Ambrosio L, Salfi C, Gammaitoni L, Giraudo L, Pisacane A, Butera S, Pignochino Y, Basiricó M, Capozzi F, Sapino A, Aglietta M, Sangiolo D (2018) Cytokine induced killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy. Oncoimmunology 7:e1465161

    Article  PubMed  PubMed Central  Google Scholar 

  • Miao Y, Zhang H, Pan Y, Ren J, Ye M, Xia F, Huang R, Lin Z, Jiang S, Zhang Y, Songyang Z, Zhang Y (2017) Single-walled carbon nanotube: one specific inhibitor of cancer stem cells in osteosarcoma upon downregulation of the TGFβ1 signaling. Biomaterials 149:29–40

    Article  CAS  PubMed  Google Scholar 

  • Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PC (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294–305

    Article  CAS  PubMed  Google Scholar 

  • Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S, Kimura S, Wada T, Uchihashi Y, Kondo T, Yamashita T, Sato N (2009) Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 101:1425–1432

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Mutsaers AJ, Walkley CR (2014) Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone 62:56–63

    Article  PubMed  Google Scholar 

  • Najafi M, Farhood B, Mortezaee K (2019) Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol 234(6):8381–8395

    Article  CAS  PubMed  Google Scholar 

  • Paiva-Oliveira DI, Martins-Neves SR, Abrunhosa AJ, Fontes-Ribeiro C, Gomes CMF (2018) Therapeutic potential of the metabolic modulator metformin on osteosarcoma cancer stem-like cells. Cancer Chemother Pharmacol 81:49–63

    Article  CAS  PubMed  Google Scholar 

  • Peng L, Jiang D (2018) Resveratrol eliminates cancer stem cells of osteosarcoma by STAT3 pathway inhibition. PLoS One 13:e0205918

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Perrot P, Rousseau J, Bouffaut AL, Rédini F, Cassagnau E, Deschaseaux F, Heymann MF, Heymann D, Duteille F, Trichet V, Gouin F (2010) Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One 5:e10999

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Qi XT, Li YL, Zhang YQ, Xu T, Lu B, Fang L, Gao JQ, Yu LS, Zhu DF, Yang B, He QJ, Ying MD (2018) KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol Sin. https://doi.org/10.1038/s41401-018-0050-6

  • Qu H, Xue Y, Lian W, Wang C, He J, Fu Q, Zhong L, Lin N, Lai L, Ye Z, Wang Q (2018) Melatonin inhibits osteosarcoma stem cells by suppressing SOX9-mediated signaling. Life Sci 207:253–264

    Article  CAS  PubMed  Google Scholar 

  • Reimann E, Kõks S, Ho XD, Maasalu K, Märtson A (2014) Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data. Hum Genomics 8:20

    PubMed  PubMed Central  Google Scholar 

  • Rubio R, Abarrategi A, Garcia-Castro J, Martinez-Cruzado L, Suarez C, Tornin J, Santos L, Astudillo A, Colmenero I, Mulero F, Rosu-Myles M, Menendez P, Rodriguez R (2014) Bone environment is essential for osteosarcoma development from transformed mesenchymal stem cells. Stem Cells 32:1136–1148

    Article  CAS  PubMed  Google Scholar 

  • Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH (2012) Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One 7:e41401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saraf AJ, Fenger JM, Roberts RD (2018) Osteosarcoma: accelerating progress makes for a hopeful future. Front Oncol 8:4

    Article  PubMed  PubMed Central  Google Scholar 

  • Sarver AE, Subramanian S (2016) Imprinting defects in osteosarcoma: DNA- and chromatin-modifying drugs hold promise for osteosarcoma therapy. Epigenomics 8:885–888

    Article  CAS  PubMed  Google Scholar 

  • Shang D, Wu J, Guo L, Xu Y, Liu L, Lu J (2017) Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2. Int J Oncol 50:1848–1856

    Article  CAS  PubMed  Google Scholar 

  • Sharma A, Capobianco E (2017) Immuno-oncology integrative networks: elucidating the influences of osteosarcoma phenotypes. Cancer Inform 16:1176935117721691

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Smida J, Xu H, Zhang Y, Baumhoer D, Ribi S, Kovac M, von Luettichau I, Bielack S, O’Leary VB, Leib-Mösch C, Frishman D, Nathrath M (2017) Genome-wide analysis of somatic copy number alterations and chromosomal breakages in osteosarcoma. Int J Cancer 141:816–828

    Article  CAS  PubMed  Google Scholar 

  • Surdez D, Guillemot D, Lapouble E, Freneaux P, Champigneulle J, Bouvier R, Walder D, Ambros IM, Hutter C, Sorz E, Amaral AT, de Álava E, Schallmoser K, Strunk D, Rinner B, Liegl-Atzwanger B, Huppertz B, Leithner A, de Pinieux G, Terrier P, Laurence V, Michon J, Ladenstein R, Holter W, Windhager R, Dirksen U, Ambros PF, Delattre O, Kovar H, Bock C, Tomazou EM (2017) DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nat Med 23:386–395

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tang N, Song WX, Luo J, Haydon RC, He TC (2008) Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466:2114–2130

    Article  PubMed  PubMed Central  Google Scholar 

  • Tellez-Gabriel M, Ory B, Lamoureux F, Heymann MF, Heymann D (2016) Tumour heterogeneity: the key advantages of single-cell analysis. Int J Mol Sci 17(12):E2142

    Article  PubMed  CAS  Google Scholar 

  • Tellez-Gabriel M, Charrier C, Brounais-Le Royer B, Mullard M, Brown HK, Verrecchia F, Heymann D (2017) Analysis of gap junctional intercellular communications using a dielectrophoresis-based microchip. Eur J Cell Biol 96:110–118

    Article  CAS  PubMed  Google Scholar 

  • Théoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Rédini F, Heymann D (2005) Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 5:123

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tian J, Li X, Si M, Liu T, Li J (2014) CD271+ osteosarcoma cells display stem-like properties. PLoS One 9:e98549

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A, Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A (2008) Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 3:e3469

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, Fazioli F, Papaccio G (2011) Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. FASEB J 25:2022–2030

    Article  CAS  PubMed  Google Scholar 

  • Vallée A, Lecarpentier Y (2018) Crosstalk between peroxisome proliferator-activated receptor gamma and the canonical WNT/β-catenin pathway in chronic inflammation and oxidative stress during carcinogenesis. Front Immunol 9:745

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Vallette FM, Olivier C, Lézot F, Oliver L, Cochonneau D, Lalier L, Cartron PF, Heymann D (2018) Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer. Biochem Pharmacol. https://doi.org/10.1016/j.bcp.2018.11.004

  • Wang L, Park P, Zhang H, La Marca F, Lin CY (2011) Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity. Int J Cancer 128:294–303

    Article  CAS  PubMed  Google Scholar 

  • Wang J, Wang D, Niu X, Wang Z, Song CL, Huang Z, Chen KN, Duan J, Bai H, Xu J, Zhao J, Wang Y, Zhuo M, Xie XS, Kang X, Tian Y, Cai L, Han JF, An T, Sun Y, Gao S, Zhao J, Ying J, Wang L, He J (2019) Multiregion sequencing reveals the genetic heterogeneity and evolutionary history of osteosarcoma and matched pulmonary metastases. Cancer Res 79(1):7–20

    Article  CAS  PubMed  Google Scholar 

  • Xi X, Wu Q, Bao Y, Zhong X, Dai X, Lin H (2019) Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma. Eur J Pharmacol 844:259–267

    Article  CAS  PubMed  Google Scholar 

  • Xu HY, Fang W, Huang ZW, Lu JC, Wang YQ, Tang QL, Song GH, Kang Y, Zhu XJ, Zou CY, Yang HL, Shen JN, Wang J (2017) Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling. Eur Rev Med Pharmacol Sci 21(20):4516–4528

    CAS  PubMed  Google Scholar 

  • Yan GN, Tang XF, Zhang XC, He T, Huang YS, Zhang X, Meng G, Guo DY, Lv YF, Guo QN (2017) TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway. Oncotarget 8:85628–85641

    Article  PubMed  PubMed Central  Google Scholar 

  • Yang M, Yan M, Zhang R, Li J, Luo Z (2011) Side population cells isolated from human osteosarcoma are enriched with tumor-initiating cells. Cancer Sci 102:1774–1781

    Article  CAS  PubMed  Google Scholar 

  • Yu L, Liu S, Zhang C, Zhang B, Simoes BM, Eyre R, Liang Y, Yan H, Wu Z, Guo W, Clarke RB (2013) Enrichment of human osteosarcoma stem cells based on hTERT transcriptional activity. Oncotarget 4:2326–2338

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhang H, Wu H, Zheng J, Yu P, Xu L, Jiang P, Gao J, Wang H, Zhang Y (2013) Transforming growth factor beta1 signal is crucial for dedifferentiation of cancer cells to cancer stem cells in osteosarcoma. Stem Cells 31:433–446

    Article  PubMed  CAS  Google Scholar 

  • Zhang D, Zhao Q, Sun H, Yin L, Wu J, Xu J, He T, Yang C, Liang C (2016) Defective autophagy leads to the suppression of stem-like features of CD271+ osteosarcoma cells. J Biomed Sci 23:82

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang RM, Tang T, Yu HM, Yao XD (2018a) LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling. Biochem Biophys Res Commun 507:260–266

    Article  CAS  PubMed  Google Scholar 

  • Zhang W, Zhao JM, Lin J, Hu CZ, Zhang WB, Yang WL, Zhang J, Zhang JW, Zhu J (2018b) Adaptive fibrogenic reprogramming of osteosarcoma stem cells promotes metastatic growth. Cell Rep 24:1266–1277

    Article  CAS  PubMed  Google Scholar 

  • Zhao D, Chen Y, Chen S, Zheng C, Hu J, Luo S (2017) MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN. Tumour Biol 39:1010428317705341

    PubMed  Google Scholar 

  • Zou Y, Huang Y, Yang J, Wu J, Luo C (2017) miR-34a is downregulated in human osteosarcoma stem-like cells and promotes invasion, tumorigenic ability and self-renewal capacity. Mol Med Rep 15:1631–1637

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. INSERM, European Associated Laboratory “Sarcoma Research Unit”, Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK

    Kristina Schiavone & Dominique Heymann

  2. INSERM, Institut de Cancérologie de l’Ouest, CRCINA, Université de Nantes, Université d’Angers, Saint Herblain, France

    Delphine Garnier, Marie-Francoise Heymann & Dominique Heymann

Authors
  1. Kristina Schiavone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Delphine Garnier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marie-Francoise Heymann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dominique Heymann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dominique Heymann .

Editor information

Editors and Affiliations

  1. Department of Pathology, Federal University of Minas Gerais, Department of Radiology, Columbia University Medical Center, New York, NY, USA, Belo Horizonte, MG, Brazil

    Alexander Birbrair

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schiavone, K., Garnier, D., Heymann, MF., Heymann, D. (2019). The Heterogeneity of Osteosarcoma: The Role Played by Cancer Stem Cells. In: Birbrair, A. (eds) Stem Cells Heterogeneity in Cancer. Advances in Experimental Medicine and Biology, vol 1139. Springer, Cham. https://doi.org/10.1007/978-3-030-14366-4_11

Download citation

Publish with us

Policies and ethics

Search

Navigation